Yüklüyor......
The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90)
Aims Two open studies in healthy volunteers were conducted to determine the absolute bioavailability and metabolic disposition of zolmitriptan (311C90), a novel 5HT(1D) agonist for the acute treatment of migraine. Methods After an initial test i.v. infusion, bioavailabilty was assessed by comparison...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Wiley-Blackwell
1997
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2042784/ https://ncbi.nlm.nih.gov/pubmed/9205817 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1997.00614.x |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|